CCK-8S inhibits L-dopa-induced dyskinesias in parkinsonian squirrel monkeys.

CCK-8S inhibits L-dopa-induced dyskinesias in parkinsonian squirrel monkeys.

Systemic administration of CCK-8S (1 or 10 micrograms/kg IP) markedly inhibited L-dopa-induced dyskinesias in parkinsonian monkeys, but did not interfere with locomotor stimulation by L-dopa. CCK analogues may be useful antidyskinetic agents for improved control of Parkinson's disease.

Opis bibliograficzny
Główni autorzy:	Boyce, S, Rupniak, N, Steventon, M, Iversen, S
Format:	Journal article
Język:	English
Wydane:	1990

Podobne zapisy

Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys.
od: Boyce, S, i wsp.
Wydane: (1990)

Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys.
od: Boyce, S, i wsp.
Wydane: (1990)

Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys.
od: Rupniak, N, i wsp.
Wydane: (1992)

(+)-PHNO: a new anti-parkinsonian agent which does not induce chorea in MPTP-treated squirrel monkeys.
od: Rupniak, N, i wsp.
Wydane: (1990)

NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys.
od: Tye, S, i wsp.
Wydane: (1989)

Spontaneous orofacial dyskinesias in a captive cynomolgus monkey: implications for tardive dyskinesia.
od: Rupniak, N, i wsp.
Wydane: (1990)

DIFFERENTIAL-EFFECTS OF D-1 AND D-2 DOPAMINE AGONISTS IN MPTP-TREATED SQUIRREL-MONKEYS
od: Boyce, S, i wsp.
Wydane: (1990)

BLOCKADE OF CCK-B RECEPTORS BY L-365,260 INDUCES ANALGESIA IN THE SQUIRREL-MONKEY
od: Oneill, M, i wsp.
Wydane: (1990)

Modulatory role for CCK-B antagonists in Parkinson's disease.
od: Boyce, S, i wsp.
Wydane: (1990)

Blockade of CCK-B receptors by L-365,260 induces analgesia in the squirrel monkey.
od: O'Neill, M, i wsp.
Wydane: (1990)

Effect of a selective glutamate antagonist on l-dopa-induced dyskinesias in drug-naive parkinsonian monkeys
od: Abdallah Hadj Tahar, i wsp.
Wydane: (2004-03-01)

Propranolol Relieves L-Dopa-Induced Dyskinesia in Parkinsonian Mice
od: Ziqing Shi, i wsp.
Wydane: (2020-11-01)

Therapeutic efficacy of a novel transdermal delivery system for (+)-PHNO in parkinsonian squirrel monkeys.
od: Rupniak, N, i wsp.
Wydane: (1989)

7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate
od: M. T. Herrero, i wsp.
Wydane: (2023-05-01)

Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys
od: Marc Morissette, i wsp.
Wydane: (2022-02-01)

A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys
od: Daniella Rylander, i wsp.
Wydane: (2010-09-01)

Spontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats
od: Stefania eSgroi, i wsp.
Wydane: (2014-10-01)

The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study.
od: Cristina Miguelez, i wsp.
Wydane: (2011-01-01)

Dynamic Involvement of Striatal NG2-glia in L-DOPA Induced Dyskinesia in Parkinsonian Rats: Effects of Doxycycline
od: G.C. Nascimento, i wsp.
Wydane: (2023-03-01)

In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias
od: Rosario Sánchez-Pernaute, i wsp.
Wydane: (2007-08-01)

IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.
od: Romina Aron Badin, i wsp.
Wydane: (2013-01-01)

Correction: IRC-082451, a Novel Multitargeting Molecule, Reduces L-DOPA-Induced Dyskinesias in MPTP Parkinsonian Primates
Wydane: (2013-01-01)

Correction: IRC-082451, a Novel Multitargeting Molecule, Reduces L-DOPA-Induced Dyskinesias in MPTP Parkinsonian Primates.
od: Romina Aron Badin, i wsp.
Wydane: (2013-01-01)

Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid
od: Souha Mahmoudi, i wsp.
Wydane: (2009-10-01)

REVERSAL OF CCK-INDUCED HYPOLOCOMOTION IN THE MOUSE BY THE CCK-A ANTAGONIST DEVAZEPIDE BUT NOT BY THE CCK-B ANTAGONIST L-365,260
od: Oneill, M, i wsp.
Wydane: (1990)

Maladaptive synaptic plasticity in L-DOPA-induced dyskinesia
od: Qiang Wang, i wsp.
Wydane: (2016-12-01)

Circuit Mechanisms of L-DOPA-Induced Dyskinesia (LID)
od: Kai Yang, i wsp.
Wydane: (2021-03-01)

Nicotine-mediated improvement in l-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function
od: Maryka Quik, i wsp.
Wydane: (2013-02-01)

Phosphodiesterase 10A Inhibition Modulates the Corticostriatal Activity and L-DOPA-Induced Dyskinesia
od: Rayanne Poletti Guimarães, i wsp.
Wydane: (2022-07-01)

Induction of cognitive impairment by scopolamine and noncholinergic agents in rhesus monkeys.
od: Rupniak, N, i wsp.
Wydane: (1991)

Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia
od: Veronica Ghiglieri, i wsp.
Wydane: (2012-01-01)

Effects of hydrogen gas inhalation on L-DOPA-induced dyskinesia
od: Glauce C. Nascimento, i wsp.
Wydane: (2023-07-01)

Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia
od: Fabbrini A, i wsp.
Wydane: (2021-04-01)

Drug-induced purposeless chewing: animal model of dyskinesia or nausea?
od: Rupniak, N, i wsp.
Wydane: (1990)

Molecular and cellular determinants of L-Dopa-induced dyskinesia in Parkinson’s Disease
od: Federica Servillo, i wsp.
Wydane: (2024-11-01)

Targeting Striatal Glutamate and Phosphodiesterases to Control L-DOPA-Induced Dyskinesia
od: Brik A. Kochoian, i wsp.
Wydane: (2023-11-01)

Striatal plasticity in L-DOPA- and graft-induced dyskinesia; the common link?
od: Daniella eRylander Ottosson, i wsp.
Wydane: (2016-02-01)

Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia
od: Matthieu F. Bastide, i wsp.
Wydane: (2017-05-01)

Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia
od: Christine Konradi, i wsp.
Wydane: (2004-11-01)

AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys
od: Mélanie Bourque, i wsp.
Wydane: (2022-11-01)